https://realtalifesciences.com/
ReAlta Life Sciences | Pegtarazimod for Neonatal HIE Treatment
Apr 6, 2026 - ReAlta advances pegtarazimod, a Phase 2 therapy targeting hypoxic ischemic encephalopathy (HIE) to protect the newborn brain and preserve lifelong function.
life sciencesrealtapegtarazimodneonatalhie
https://www.businesswire.com/news/home/20260408027908/en/ReAlta-Life-Sciences-Closes-Oversubscribed-%2440-Million-Financing-Round-to-Advance-Pegtarazimod-Phase-2-Program-in-Hypoxic-Ischemic-Encephalopathy-HIE
ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod...
ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy
life sciences